United States POEMS Syndrome Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Baxter, Genentech Inc, Takeda Pharmaceuticals, Oncopeptides AB. Acrotech Biopharma

POEMS Syndrome Market is expected to grow at a CAGR of 5% during the forecast period 2024-2031.

Get a Free Sample Research PDF: https://www.datamintelligence.com/download-sample/poems-syndrome-market?sg

Industry Latest News 2025:
✅ 20 Feb 2025 - Medscape published an updated clinical overview of POEMS syndrome summarizing diagnosis, pathophysiology and management trends.
✅ 06 May 2025 - Mayo Clinic updated its patient/disease overview for POEMS syndrome (overview of symptoms, diagnosis importance and management).
✅ 21 May 2025 - Arnaud Jaccard et al. published a 2025 review/article titled "POEMS Syndrome" summarizing recent diagnostic and management evidence.
✅ 20 May 2025 - Oncopeptides launched a real-world evidence (RWE) study of Pepaxti and announced first patient enrollment (RWE study in Spain).
✅ 21 Aug 2025 - Oncopeptides carried out a rights issue (~SEK 150m) and provided an update on advanced discussions for a Japan partnership; company materials also note Pepaxti's inclusion in European myeloma guidance.
✅ 03 Nov 2025 - Oncopeptides announced planned presentations and corporate updates tied to recent real-world and registry data for Pepaxti (Q3/late-2025 reporting and conference abstracts).

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports): https://www.datamintelligence.com/buy-now-page?report=poems-syndrome-market?sg

Market Geographical Share:
• North America dominates the POEMS syndrome market owing to strong healthcare infrastructure, advanced diagnostic capabilities, and higher disease awareness. The United States accounts for the largest share, supported by a concentration of research institutions and patient registries focused on plasma cell disorders. Increasing use of autologous stem cell transplantation and availability of novel biologic therapies are further strengthening market presence in this region.

• Europe holds the second-largest share, driven by expanding access to specialized hematology centers and clinical trials across countries such as Germany, the United Kingdom, France, and Italy. Government initiatives to promote orphan drug development and faster regulatory approvals have encouraged biopharmaceutical companies to target this region. Collaborative research programs through the European Hematology Association and cross-border clinical studies continue to boost diagnosis and treatment adoption.

• The Asia-Pacific region is emerging as a high-potential market due to increasing healthcare expenditure, growing diagnostic capabilities, and improving awareness of rare diseases. Japan, China, and South Korea are witnessing a gradual rise in POEMS syndrome diagnosis rates due to improved imaging and electrophysiological testing. Rapid adoption of advanced chemotherapy and radiation therapy options, coupled with supportive reimbursement structures in Japan, contributes significantly to regional growth.

Market Drivers:
• Rising Awareness and Diagnostic Advancements: Increased understanding of rare plasma cell disorders and improved access to diagnostic modalities such as electromyography (EMG), MRI, and serum protein electrophoresis have enhanced early detection rates.

• Growing Research on Pathogenesis and Treatment: Ongoing clinical studies focusing on immunomodulatory drugs, targeted therapies, and stem cell transplantation are expanding treatment possibilities and improving prognosis.

• Government and Regulatory Support: Supportive orphan drug designations and faster approval processes for rare disease therapies have encouraged innovation and market entry of new treatment options.

• Increased Collaboration and Patient Registries: Partnerships between academic centers, hospitals, and rare disease organizations are enabling data sharing, aiding in patient identification and longitudinal studies.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/poems-syndrome-market?sg

By Diagnosis Type
• EMG & nerve conduction studies remain foundational for initial neuropathy workups, driving steady usage in neurology clinics and hospitals; they are low-cost but essential for clinical suspicion.
• Blood/urine tests (M-protein detection, VEGF levels, immunofixation, serum/urine protein electrophoresis) are increasing in share because lab biomarkers (especially VEGF and monoclonal protein testing) improve diagnostic certainty and enable earlier referral to hematology.
• Imaging (X-ray, CT, PET/CT) uptake is rising for staging and to identify sclerotic bone lesions and FDG-avid plasmacytomas; PET/CT use is growing where available.
• Biopsy (bone marrow or nerve biopsy) remains critical for confirmatory diagnosis in many cases and supports therapeutic choice (ASCT vs systemic therapy).

By Treatment Type
• Anti-plasma cell therapy (high-dose chemotherapy + autologous stem cell transplant (ASCT), combination chemotherapies, and increasingly IMiDs and proteasome inhibitors such as lenalidomide, bortezomib) are the core of disease-directed care; these options drive the majority of therapeutic spend. ASCT remains a key curative/major modality where patients are eligible.
• Radiation therapy is widely used for localized plasmacytomas and often delivers high clinical value for limited disease; its share is meaningful in settings with focal disease.
• Physical therapy and rehabilitation is an important supportive segment (neuropathy rehabilitation, mobility aids), growing as survivorship improves.

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?sg

Market Key Players:
Key players are Bristol-Myers Squibb Company, Baxter, Genentech USA, Inc., Takeda Pharmaceuticals U.S.A., Inc., Oncopeptides AB. Acrotech Biopharma, LLC., LGM PHARMA, Jubilant and Cadista Pharmaceuticals Inc.

• Bristol-Myers Squibb (BMS) - Manufacturer/rights holder (Celgene legacy) of lenalidomide (Revlimid) an immunomodulatory drug widely reported in studies and pilot trials as an effective systemic option for POEMS syndrome.

• Baxter - Provides hospital and supportive care products (IVIG, infusion systems, critical-care supplies) commonly used in the inpatient/supportive management of complex hematology patients - plays a supportive, non-disease-specific role in POEMS care rather than offering a POEMS-labelled drug.

• Genentech (Roche Group) - Major oncology company with hematology/oncology portfolio and historical study collaborations in myeloma space (Genentech has partnered on studies combining myeloma agents). While not known to market a POEMS-specific drug, Genentech's oncology capabilities are relevant to combination regimens and research collaborations in plasma-cell disorders.

• Takeda Pharmaceuticals U.S.A., Inc. - Developer/marketer of VELCADE® (bortezomib) a proteasome inhibitor widely reported in the literature as an effective option in POEMS therapy.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.